Neuroscience

Human brain
#Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial #Teitur Trophics

Phase I trial shows Parkinson’s peptide crosses blood-brain barrier

Teitur Trophics has announced successful results from its Phase I clinical trial of lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD).  The data show TT-P34 crosses the blood-brain barrier, leading to robust, dose-dependent exposure within the brain and central nervous system (CNS). Read More

#News

Neuroscience concept
#Biomarkers #Drug discovery #Neuroscience

What broken livers taught me about the brain 

Jack O'Meara CEO and Co-Founder of Aerska, compares the cardiovascular field to advances in neuroscience and how a preventative approach could be on the horizon for diseases such as Alzheimer’s.   At Ochre Bio, the company I ran before Aerska, we spent years keeping human livers alive outside the body. Organs turned down for transplant, hooked up to a perfusion machine,… Read More

#Exclusive Content

Human neuron
#Autism #Connectome #MRC Laboratory of Molecular Biology #Neuroscience #Schizophrenia

Male fly brain offers new avenues for neuroscience

Scientists have mapped every connection in the brain and nerve cord of an adult male animal, unlocking insights into the neural mechanisms that shape behaviour. Known in scientific terms as a ‘connectome’, the team have produced a wiring map of the 166,700 neurons and the millions of connections between them. Read More

#News

#epilepsy #Mergers and acquisitions #Neuroscience

SK Biopharmaceuticals licences epilepsy drug from Biohaven

Biohaven and SK Biopharmaceuticals have agreed a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven's Kv7 ion channel platform.  The platform is led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase II/III development for focal epilepsy,… Read More

#Business & Investment #News

Tau proteins
#Alzheimer's #Funding #Neurodegenerative disorders #Neuroscience

Four scientists awarded $3m for tau-driven disease research

A group of charities have announced $3 million in grants to fund four innovative research projects over two years, stemming from the 2026 Tauopathy Challenge Workshop.   The Rainwater Charitable Foundation, in collaboration with the Alzheimer’s Association, the Aging Mind Foundation, and CurePSP, will fund the proposals based… Read More

#News

Neurons
#Amyotrophic lateral sclerosis (ALS) #Neurodegenerative disorders #Neuroscience #NRG Therapeutics

New drug displays anti-inflammatory and neuroprotective effects in ALS

NRG Therapeutics has shared preclinical and mechanistic data of its lead clinical asset NRG5051, a treatment for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), and Parkinson’s.  NRG disclosed that NRG5051, a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial permeability transition… Read More

#Editor's Choice #News

#Financing #Kynexis #Neuroscience #Phase II trial #Schizophrenia

Kynexis extends Series A to €97m to advance cognitive disorder drug

Kynexis has closed a €40 million Series A extension bringing the company’s total Series A financing to €97 million ($110 million).   The financing was led by new investor Novartis Venture Fund, with participation from existing investors Forbion, Ysios Capital, and Sunstone Life Science Ventures.   In connection with the financing, Novartis… Read More

#Business & Investment #News

AI brain
#Amyotrophic lateral sclerosis (ALS) #Cumulus Neuroscience #Digital health #Frontotemporal Dementia (FTD) #Neuroscience #Research Ireland #Trinity College Dublin

Platform could improve ALS and FTD trial endpoints 

Cumulus Neuroscience, a global digital health company, has published final results from its first-in-class CNS-102 study in Scientific Reports. The study was conducted in collaboration with the PRECISIONALS initiative, a Research Ireland academic–industry collaboration hosted by Trinity College Dublin.  The paper, titled “Longitudinal cognitive assessment using the Cumulus NeuLogiq Platform in… Read More

#News

Neurones in the brain
#Leadership appointment #MindMaze Therapeutics #Neuroplasticity #Neuroscience #New appointment

MindMaze Therapeutics appoints strategic advisor for US growth

MindMaze Therapeutics has appointed Dr John Krakauer as a strategic advisor to support its next phase of growth in the United States.  “John has shaped the science behind our platform for years, and his foundational work is central to how we think about recovery,” said Zach Henderson, CEO of MindMaze Therapeutics. “As… Read More

#News

Neurons
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #US Food and Drug Administration (FDA)

Immunotherapy for Parkinson’s gets FDA Fast Track Designation

AC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD).  ACI-7104 is designed to induce a-syn-specific antibodies, preferentially recognising aggregated… Read More

#Editor's Choice #News #Regulatory

Neurons
#MindMaze Therapeutics #Neurology #Neuroscience

MindMaze Therapeutics refocuses efforts on neurology

MindMaze Therapeutics has announced the completion of its organisational simplification initiative, and the implementation of its CHF 8 ($9.8) million strategic equity financing with Neuro.io Group.  The company’s organisational simplification initiative included the selling of substantially all remaining non-neurology legacy operations acquired through its business combination with Relief Therapeutics.   The… Read More

#Business & Investment #News

#AstronauTx #Mergers and acquisitions #Neurology #Neuroscience

AstronauTx acquires neurological disease programme from Saniona

AstronauTx has secured the exclusive worldwide rights to research, develop, manufacture and commercialise therapeutic candidates arising from its collaboration with biopharma company Saniona.  Saniona and AstronauTx entered into a research collaboration and option agreement in 2023 to discover new treatments for neurological conditions by modulating a novel, undisclosed ion channel… Read More

#Business & Investment #News

Parkinson's disease
#BioVie #Neuroscience #Parkinson's #Phase II trial

Trial shows significant improvements in early Parkinson’s disease

BioVie has announced results from its Phase II SUNRISE-PD trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease (PD).  The SUNRISE-PD trial was a Phase II, multicentre, randomised, double-blind, placebo-controlled trial designed to establish proof-of-mechanism and proof-of-concept in patients with early-stage PD that had not previously… Read More

#Editor's Choice #News

Claus Sundgreen
#Appointment #Neuroscience #New appointment #NRG Therapeutics

NRG Therapeutics appoints neuroscience leader as CMO

NRG Therapeutics has announced the appointment of Dr Claus Sundgreen as Chief Medical Officer (CMO), effective from 1 August 2026.  A recognised leader in neuroscience drug development with expertise in ALS, Dr Sundgreen brings over 25 years of clinical leadership with experience spanning translational medicine and all… Read More

#News

Neurons in the brain
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

Learn about neuroscience drug discovery in this free webinar

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News

Neuroscience concept
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

Register now: The advances in neuroscience drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of… Read More

#News